Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.
about
Vitamin D and Osteoporosis in HIV/HCV Coinfected Patients: A Literature ReviewAnti-Inflammatory and Antimicrobial Actions of Vitamin D in Combating TB/HIVVitamin D supplementation for preventing infections in children under five years of age.Micronutrient supplementation in adults with HIV infection.Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals.Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial.Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach.High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial.Vitamin D₃supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trialMicronutrients in HIV: a Bayesian meta-analysis.Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.Vitamin D and bone loss in HIVSafety and Efficacy of High-Dose Daily Vitamin D3 Supplementation in Children and Young Adults Infected With Human Immunodeficiency VirusBone health in HIV-infected children and adolescents.Metabolic complications and treatment of perinatally HIV-infected children and adolescents.Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein.Cholecalciferol 20 000 IU Once Weekly in HIV-Positive Patients with Low Vitamin D Levels: Result from a Cohort Study.Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth.Effects of Vitamin D Supplementation on Bone Mineral Density and Bone Markers in HIV-infected Youth.Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial.Prevalence of hypovitaminosis D and its association with oral lesions in HIV-infected Brazilian adults.Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients.Different strategies of 25OH vitamin D supplementation in HIV-positive subjects.Vitamin D Insufficiency/Deficiency in HIV-Infected Inner City Youth.Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with HIV Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation.Effect of calcium and vitamin D supplementation on bone mineral accrual among HIV-infected Thai adolescents with low bone mineral density.Vitamin D in pediatric age: consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians.
P2860
Q26798289-6A16A872-541B-497F-B0C9-E3454899FA0EQ27011921-3FB635F7-5413-4A5D-9D3C-78531F152516Q30241581-7797664E-BF95-413F-A6A1-3BA73D6F6F17Q33761301-DE707EA6-6262-4818-9EFC-A13D0C1E483FQ34016783-7E053184-69D7-4249-8B53-85FDDD23D2A5Q34054004-7E49D3A9-E091-4CD4-A062-6AD286273447Q34340891-12F69348-617B-4071-AD43-BB4F34A67D63Q34570942-B4807E97-94EF-4950-B00E-26746E586D22Q34799320-E0988B5F-23F7-40B2-8B1D-6AF4A1A81AAFQ35113182-85BE62FA-05A7-4D6E-865C-6A6584FE8577Q35241827-FFE4BE77-8526-4314-93C5-30E354AFE18CQ35962186-F91B9618-D590-45C5-AD3A-D151851015B2Q36816930-98F83F5E-AA5D-40F8-9E54-C0712A725153Q36862311-31553CCF-174E-4359-BB77-0A7606712A9DQ36882631-162B6AEA-C814-4A4F-824E-E7E2461F43B4Q36952291-0F19C2D5-DAE9-448A-8294-536723421463Q37263395-81D8C85E-A773-4ACB-852F-8E074E43B8ADQ37307158-8A254474-8D3B-496D-8BF8-A0516EC84E3AQ38844898-7AFAB8B5-2433-4CCB-8D92-62B427D74F4CQ38978858-89A8913D-A720-4CC9-AE93-F7A7684CE330Q40049023-B28781EE-BF28-49DA-8588-85A25A849C26Q40455005-C3C5BC3B-E89F-4C56-9955-AC8DD792017EQ40680683-4AE837D3-82B5-4281-BCEE-D92E72D3B3EFQ41644519-436B29E0-00C2-4D95-A013-8F8EFAE8496CQ42230910-02F324F5-2B85-4214-AD3B-CB3220A92B14Q42281798-0A3371B5-293A-413F-96C4-AEBFEE4687D3Q46099287-9DB985DF-50CA-4FDA-BF97-F7C6E37980E5Q47159869-737E93C4-E43C-4122-934D-41A04DE9438AQ54250402-382224D6-238E-44C9-BC5B-37D163E460F2Q55074474-AE8964DD-5604-420F-8360-C988E5B78EBD
P2860
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Serum 25-hydroxyvitamin D resp ...... in youth with HIV-1 infection.
@ast
Serum 25-hydroxyvitamin D resp ...... in youth with HIV-1 infection.
@en
type
label
Serum 25-hydroxyvitamin D resp ...... in youth with HIV-1 infection.
@ast
Serum 25-hydroxyvitamin D resp ...... in youth with HIV-1 infection.
@en
prefLabel
Serum 25-hydroxyvitamin D resp ...... in youth with HIV-1 infection.
@ast
Serum 25-hydroxyvitamin D resp ...... in youth with HIV-1 infection.
@en
P2093
P2860
P356
P1476
Serum 25-hydroxyvitamin D resp ...... in youth with HIV-1 infection.
@en
P2093
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team
Bill G Kapogiannis
Brandy Rutledge
Charles B Stephensen
Craig M Wilson
Jorge Lujan-Zilbermann
Kathleen Mulligan
Marta D Van Loan
Patricia Flynn
Peter L Havens
P2860
P304
P356
10.1210/JC.2012-2600
P407
P577
2012-08-29T00:00:00Z